专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130123248A1 PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION 审中-公开
标题翻译：阳性AMPA受体调节剂对神经营养因子表达的药理学调节
公开(公告)号：US20130123248A1
公开(公告)日：2013-05-16
申请号：US13654366
申请日：2012-10-17
申请人： Julie C. Lauterborn , Christine M. Gall , Gary Lynch
发明人： Julie C. Lauterborn , Christine M. Gall , Gary Lynch
IPC分类号： A61K45/06 , A61K31/44 , A61K31/5365
CPC分类号： A61K45/06 , A61K31/44 , A61K31/4439 , A61K31/5365 , A61K2300/00
摘要： Antagonists of group 1 metabotropic glutamate receptors (mGluR) potentiate the effect of positive AMPA receptor modulators on neurotrophin expression, such as brain-derived neurotrophic factor (BDNF). The findings described herein suggest a combinatorial approach for drug therapies, using both positive AMPA receptor modulators and mGluR antagonists, to enhance brain neurotrophism.
摘要翻译：第1组代谢型谷氨酸受体（mGluR）的拮抗剂增强阳性AMPA受体调节剂对神经营养因子表达的影响，如脑源性神经营养因子（BDNF）。本文所述的发现表明药物治疗的组合方法，使用阳性AMPA受体调节剂和mGluR拮抗剂，以增强脑神经营养。

2. 发明申请

US20110306601A1 PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION 审中-公开
标题翻译：阳性AMPA受体调节剂对神经营养因子表达的药理学调节
公开(公告)号：US20110306601A1
公开(公告)日：2011-12-15
申请号：US13213419
申请日：2011-08-19
申请人： Julie C. Lauterborn , Christine M. Gall , Gary Lynch
发明人： Julie C. Lauterborn , Christine M. Gall , Gary Lynch
IPC分类号： A61K31/55 , A61K31/4439 , A61K31/4168 , A61K31/498 , A61K31/453 , A61P25/16 , A61K31/454 , A61K31/4433 , A61K31/549 , A61P25/28 , A61P25/00 , A61P25/18 , A61K31/44 , A61K31/5365
CPC分类号： A61K45/06 , A61K31/44 , A61K31/4439 , A61K31/5365 , A61K2300/00
摘要： Antagonists of group 1 metabotropic glutamate receptors (mGluR) potentiate the effect of positive AMPA receptor modulators on neurotrophin expression, such as brain-derived neurotrophic factor (BDNF). The findings described herein suggest a combinatorial approach for drug therapies, using both positive AMPA receptor modulators and mGluR antagonists, to enhance brain neurotrophism.
摘要翻译：第1组代谢型谷氨酸受体（mGluR）的拮抗剂增强阳性AMPA受体调节剂对神经营养因子表达的影响，如脑源性神经营养因子（BDNF）。本文所述的发现表明药物治疗的组合方法，使用阳性AMPA受体调节剂和mGluR拮抗剂，以增强脑神经营养。

3. 发明申请

US20090192199A1 PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION 审中-公开
标题翻译：阳性AMPA受体调节剂对神经营养因子表达的药理学调节
公开(公告)号：US20090192199A1
公开(公告)日：2009-07-30
申请号：US12297616
申请日：2007-04-19
申请人： Julie C. Lauterborn , Christine M. Gall , Gary Lynch
发明人： Julie C. Lauterborn , Christine M. Gall , Gary Lynch
IPC分类号： A61K31/4439 , A61K31/42 , A61K31/435 , A61K31/4164 , A61P25/28
CPC分类号： A61K45/06 , A61K31/44 , A61K31/4439 , A61K31/5365 , A61K2300/00
摘要： Antagonists of group 1 metabotropic glutamate receptors (mGluR) potentiate the effect of positive AMPA receptor modulators on neurotrophin expression, such as brain-derived neurotrophic factor (BDNF). The findings described herein suggest a combinatorial approach for drug therapies, using both positive AMPA receptor modulators and mGluR antagonists. to enhance brain neurotrophism.
摘要翻译：第1组代谢型谷氨酸受体（mGluR）的拮抗剂增强阳性AMPA受体调节剂对神经营养因子表达的影响，如脑源性神经营养因子（BDNF）。本文所述的发现表明药物治疗的组合方法，使用阳性AMPA受体调节剂和mGluR拮抗剂。以增强脑神经营养。

4. 发明授权

US5998139A Assay for determination of neuronal activity in brain tissue 失效
标题翻译：测定脑组织中的神经元活性
公开(公告)号：US5998139A
公开(公告)日：1999-12-07
申请号：US838769
申请日：1997-04-10
申请人： Gary Lynch , Richard Granger , Christine M. Gall , Linda C. Palmer
发明人： Gary Lynch , Richard Granger , Christine M. Gall , Linda C. Palmer
IPC分类号： C12Q1/68 , C07H21/04 , C12Q1/08
CPC分类号： C12Q1/6809 , C12Q1/6841 , C12Q1/6883 , C12Q2600/136 , C12Q2600/158
摘要： The activation of neurons in specific areas of a mammalian brain are determined by measurement of levels of mRNA following administration of an agent that potentially affects neuronal activity. Differential levels of mRNA caused by an agent can be measured, as can the specific distribution of the alteration of neuronal activity. Many mental disorders are associated with the abnormal function of a particular area of the brain. The present invention allows the determination of which area of the brain, if any, is affected by an administered agent. Accordingly, the invention provides a valuable tool for assaying compounds as potential therapeutic agents.
摘要翻译：在哺乳动物脑的特定区域中的神经元的激活通过在施用潜在影响神经元活性的试剂后测量mRNA的水平来确定。可以测量由药剂引起的mRNA的差异水平，以及神经元活性改变的具体分布。许多精神障碍与脑的特定区域的异常功能相关。本发明允许确定脑的哪个区域（如果有的话）受给药剂的影响。因此，本发明提供了用于测定化合物作为潜在治疗剂的有价值的工具。

5. 发明授权

US07186521B2 Determining the effect of a substance on sequestration, uptake, and accumulation of amyloid in brain cells 失效
标题翻译：确定物质对脑细胞淀粉样蛋白的螯合，摄取和积累的影响
公开(公告)号：US07186521B2
公开(公告)日：2007-03-06
申请号：US09961381
申请日：2001-09-25
申请人： Gary Lynch , Xiaoning Bi , Christine M. Gall
发明人： Gary Lynch , Xiaoning Bi , Christine M. Gall
IPC分类号： C12Q1/02 , G01N33/53 , C12N5/00
CPC分类号： C07K14/775 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2267/0312 , A01K2267/0318 , C12N15/8509 , G01N33/5058 , G01N33/6896 , G01N2800/52
摘要： The present invention provides brain cells, such as normal brain cells, apolipoprotein E deficient brain cells, or apoE4 containing brain cells, that are treated with a compound which can modulate integrins and/or integrin receptors to produce increased sequestration of and/or accumulation of and/or uptake of Aβ, and/or changes in cathepsin D content and/or lysosomal dysfunction, and/or microglia activation in the brain cells. The present invention also provides methods for producing such cells and methods for using the cells for screening an agent or substance that modulates the sequestration of and/or accumulation of and/or uptake of Aβ, and/or lysosomal dysfunction, and/or changes in cathepsin D content and/or microglia activation in the brain cells. The method further provides a new therapeutic target, antagonism of glutamate receptors, for the treatment of neurodegenerative diseases which are characterized by inter alia, abnormal amyloid uptake and/or accumulation.
摘要翻译：本发明提供脑细胞，例如正常脑细胞，载脂蛋白E缺乏型脑细胞或含有apoE4的脑细胞，其可用可调节整联蛋白和/或整联蛋白受体的化合物治疗以产生增加的聚集和/或累积的和/或吸收Abeta，和/或组织蛋白酶D含量和/或溶酶体功能障碍的变化，和/或脑细胞中的小胶质细胞激活。本发明还提供了用于产生这种细胞的方法和使用细胞筛选调节Abeta和/或溶酶体功能障碍的螯合和/或积累和/或摄取和/或溶酶体功能障碍和/或变化的试剂或物质的方法脑组织蛋白酶D含量和/或小胶质细胞激活。该方法进一步提供了治疗神经变性疾病的新的治疗靶标，谷氨酸受体的拮抗作用，其特征在于特异性淀粉样蛋白摄取和/或积累。

6. 发明申请

US20060164447A1 Ethernet and USB powered printers and methods for supplying ethernet and USB power to a printer 有权
公开(公告)号：US20060164447A1
公开(公告)日：2006-07-27
申请号：US11336089
申请日：2006-01-20
申请人： David Poole , Douglas Fox , Robert Ehrhardt , Eugene Brown , Rod DeMay , John Ham , Gary Lynch , Donald Thielen
发明人： David Poole , Douglas Fox , Robert Ehrhardt , Eugene Brown , Rod DeMay , John Ham , Gary Lynch , Donald Thielen
IPC分类号： B41J29/38
CPC分类号： G06F3/1221 , B41J29/393 , G06F3/1215 , G06F3/1229 , G06F3/1286 , G06K15/4055
摘要： Ethernet and Universal Serial Bus (USB) powered printing devices are provided. In particular, Ethernet and USB powered printers and methods of Ethernet powering of printers that support high speed printing and/or data intensive printing. Such high-speed and/or data intensive printing operations are able to be Ethernet or USB powered by providing for a power storage unit within the printer device that is able be charged during non-printing periods and provide for necessary energy bursts to support such higher powered processes. In addition, the present invention provides for devices and methods that allow for printers to operate with main power provided by conventional power mains and for back-up or secondary power to be supplied by Ethernet or USB power. Additionally, the invention provides for Ethernet or USB powering, both primary and back-up, of the data and configuration settings in the printer control and image generating electronics. In the back-up power mode, the Ethernet or USB power insures that data and configurations are not lost during periods of main power outage. The invention also provides a printer and method that can optimize a printing operation, e.g., by adjusting the speed of the printing operation according to the power required for the operation and/or the power available.

7. 发明授权

US06466816B2 Method and apparatus for assessing susceptibility to stroke 失效
公开(公告)号：US06466816B2
公开(公告)日：2002-10-15
申请号：US09907914
申请日：2001-07-19
申请人： Richard Granger , Gary Lynch
发明人： Richard Granger , Gary Lynch
IPC分类号： A61B500
CPC分类号： A61B5/0476
摘要： A method is described for facilitating assessment of susceptibility to stroke. Electrical signals are collected from the brain of a patient under assessment. Data corresponding to the signals is then compared to a standard. The standard may represent a neural electrical signal taken from a person known to be susceptible to stroke. A positive comparison suggests susceptibility of the patient to stroke. The comparison can be used to characterize neural blood flow and the degree of susceptibility. This can be used in determining the need for additional testing and/or appropriate therapy. This information can also be used in categorizing the patient to determine enrollment in clinical trials. Alternatively, the standard represents a neural signal taken at an earlier time from the patient under assessment. A positive comparison suggests that the condition of the patient is unchanged. A negative comparison suggests that the neural activity of the patient has changed, implying changes in neural blood flow. This can suggest susceptibility.

8. 发明申请

US20080176793A1 UPREGULATING ACTIVITY OR EXPRESSION OF BDNF TO MITIGATE COGNITIVE IMPAIRMENT IN ASYMPTOMATIC HUNTINGTON'S SUBJECTS 审中-公开
标题翻译：更新BDNF的活动或表达以减轻非正式HUNTINGTON项目中的认知障碍
公开(公告)号：US20080176793A1
公开(公告)日：2008-07-24
申请号：US11857190
申请日：2007-09-18
申请人： Danielle Simons , Gary Lynch , Eniko Kramar
发明人： Danielle Simons , Gary Lynch , Eniko Kramar
IPC分类号： A61K38/35 , A61K31/137 , A61K31/55 , A61K31/435 , A61K31/22 , A61K38/02 , A61K31/4439 , A61K31/405 , A61K31/197 , A61K31/554 , A61K31/138 , A61K31/439 , A61K31/404 , A61K31/565
CPC分类号： A61K31/138 , A61K31/19 , A61K31/195 , A61K31/465 , A61K31/4748 , A61K31/554 , A61K31/565
摘要： This invention provides novel methods of treatment to ameliorate or prevent cognitive disorder/dysfunction in pre- or asymptomatic subject having one or more mutations in the Huntington gene. The methods involve increasing the expression or activity of the neurotrophin BDNS in the brain of said subject.
摘要翻译：本发明提供了在亨廷顿病基因中具有一个或多个突变的前或无症状受试者中改善或预防认知障碍/功能障碍的新型治疗方法。所述方法涉及增加所述受试者脑中神经营养因子BDNS的表达或活性。

9. 发明申请

US20060276462A1 Method of treating cognitive decline due to sleep deprivation and stress 审中-公开
标题翻译：治疗睡眠剥夺和压力的认知衰退的方法
公开(公告)号：US20060276462A1
公开(公告)日：2006-12-07
申请号：US10541687
申请日：2004-01-13
申请人： Sam Deadwyler , Robert Hampson , Linda Porrino , Gary Rogers , Gary Lynch
发明人： Sam Deadwyler , Robert Hampson , Linda Porrino , Gary Rogers , Gary Lynch
IPC分类号： A61K31/538 , C07D413/02
CPC分类号： A61K31/498 , A61K31/18 , A61K31/381 , A61K31/395 , A61K31/4015 , A61K31/454 , A61K31/536 , A61K31/5365 , A61K31/5415 , A61K31/542 , C07D498/14 , C07D498/22
摘要： This invention relates to methods of use for AMPA receptor potentiator compounds and pharmaceutical compositions in the prevention and treatment of cognitive impairment as a result of acute or chronic sleep deprivation, including enhancement of receptor functioning at synapses in brain networks responsible for higher order behaviors. A still further aspect of the present invention is the use of an active agent as described above for the preparation of a medicament for the treatment of a disorder as described above.
摘要翻译：本发明涉及AMPA受体增强剂化合物和药物组合物用于预防和治疗由于急性或慢性睡眠剥夺而导致的认知障碍的方法，包括增强负责高级行为的脑网络突触中的受体功能。本发明的另一方面是如上所述的活性剂用于制备如上所述的病症治疗药物的用途。

10. 发明授权

US06329368B1 Endocrine modulation with positive modulators of AMPA type glutamate receptors 失效
标题翻译：内分泌调节与AMPA型谷氨酸受体的正调节剂
公开(公告)号：US06329368B1
公开(公告)日：2001-12-11
申请号：US08853221
申请日：1997-05-09
申请人： Peter Van Der Klish , Gary Lynch
发明人： Peter Van Der Klish , Gary Lynch
IPC分类号： A61K3154
CPC分类号： A61K31/55 , A61K31/00 , A61K31/4025 , A61K31/44 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/4453 , A61K31/453 , A61K31/5365
摘要： Methods for modulating the endocrine system of a mammal are provided. In the subject methods, a positive allosteric modulator of AMPA receptors of the hypothalamus are administered to the host. The subject methods find use in applications where it is desired to increase the circulatory level of a hormone in a mammalian host, such as diseased states characterized by abnormally depressed circulatory levels of the hormone.
摘要翻译：提供了调节哺乳动物内分泌系统的方法。在本方法中，向宿主施用下丘脑AMPA受体的正变构调节剂。本发明方法可用于需要增加哺乳动物宿主中激素循环水平的应用，例如以激素异常下降的循环水平为特征的病态。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式